Trials / Completed
CompletedNCT03322020
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Men With Intermediate- or High-risk Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively. The investigators plan to evaluate the toxicity of two dose groups and decide the appropriate dose for Cyberknife boost. Also, PSA control will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Cyberknife boost 18 Gy | pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx |
| RADIATION | Cyberknife boost 21 Gy | pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx |
Timeline
- Start date
- 2016-03-21
- Primary completion
- 2018-06-30
- Completion
- 2019-06-30
- First posted
- 2017-10-26
- Last updated
- 2019-07-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03322020. Inclusion in this directory is not an endorsement.